知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

253 条记录 (耗时 0.063 秒)

    Transgenic Mice Over-Expressing Receptor For Advanced Glycation Endproduct (RAGE) In Brain And Uses Thereof
    22.
    发明申请
    Transgenic Mice Over-Expressing Receptor For Advanced Glycation Endproduct (RAGE) In Brain And Uses Thereof 失效
    转基因小鼠过表达受体高级糖化终产物（RAGE）在大脑及其应用

    公开(公告)号：US20110126298A1

    公开(公告)日：2011-05-26

    申请号：US12908832

    申请日：2010-10-20

    申请人： David M. Stern ,  Ann Marie Schmidt ,  Shi Du Yan

    发明人： David M. Stern ,  Ann Marie Schmidt ,  Shi Du Yan

    IPC分类号： A01K67/027 ,  G01N33/48

    CPC分类号： A01K67/0275 ,  A01K67/0278 ,  A01K2217/052 ,  A01K2217/15 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/035 ,  A01K2267/0356 ,  C07K14/70503 ,  C12N15/8509

    摘要： The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and the DNA sequence which encodes the receptor for advanced glycation endproducts (RAGE) are operatively linked to each other and integrated in the genome of the non-human animal, and wherein said non-human animal exhibits a reduced amount of cerebral tissue infarcted following a transient middle cerebral artery occlusion compared to an identical non-human animal lacking said DNA sequence.

    摘要翻译： 本发明提供一种转基因非人动物，其细胞含有DNA序列，其包含：（a）神经组织特异性启动子; （b）编码晚期糖基化终产物（RAGE）的受体的DNA序列，其中编码晚期糖基化终产物（RAGE）的受体的启动子和DNA序列可操作地相互连接并整合到 非人动物，并且其中所述非人动物与缺乏所述DNA序列的相同的​​非人动物相比，在短暂的大脑中动脉闭塞之后表现出减少的脑组织数量。

    Gene disruptions, compositions and methods relating thereto
    23.
    发明授权
    Gene disruptions, compositions and methods relating thereto 失效
    基因破坏，组合物和方法

    公开(公告)号：US07947866B2

    公开(公告)日：2011-05-24

    申请号：US11577547

    申请日：2005-10-18

    申请人： Mary Jean Sparks

    发明人： Mary Jean Sparks

    IPC分类号： G01N33/00

    CPC分类号： A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/035

    摘要： The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331, PRO354, PRO355, PRO533, PRO541, PRO725, PRO937, PRO1014, PRO1120, PRO1182, PRO1325, PRO1382, PRO1410, PRO1555, PRO1556, PRO1760, PRO1787, PRO1868, PRO4326, PRO4332, PRO4346, PRO4400, PRO6003, PRO6094, PRO6244, PRO9820, PRO9828, PRO10274, PRO16090, PRO19644, PRO21340, PRO92165, PRO85143, PRO1124, PRO1026 or PRO23370 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders; cardiovascular, endothelial or angiogenic disorders; eye abnormalities; immunological disorders; oncological disorders; bone metabolic abnormalities or disorders; lipid metabolic disorders; or developmental abnormalities.

    摘要翻译： 本发明涉及转基因动物，以及与基因功能表征相关的组合物和方法。 具体地，本发明提供转基因小鼠，其包括PRO194，PRO220，PRO241，PRO284，PRO331，PRO354，PRO355，PRO533，PRO541，PRO725，PRO937，PRO1014，PRO1120，PRO1182，PRO1325，PRO1382，PRO1410，PRO1555，PRO1556，PRO1760中的中断 ，PRO1787，PRO1868，PRO4326，PRO4332，PRO4346，PRO4400，PRO6003，PRO6094，PRO6244，PRO9820，PRO9828，PRO10274，PRO16090，PRO19644，PRO21340，PRO92165，PRO85143，PRO1124，PRO1026或PRO23370基因。 这样的体内研究和表征可以提供有用的识别和发现治疗和/或治疗用于预防，改善或矫正与基因中断相关的疾病或功能障碍如神经障碍; 心血管，内皮或血管生成障碍; 眼睛异常; 免疫学障碍; 肿瘤疾病; 骨代谢异常或障碍; 脂代谢紊乱 或发育异常。

    Biological substance nesfatin and its related substances and uses thereof
    25.
    发明授权
    Biological substance nesfatin and its related substances and uses thereof 失效
    生物物质nesfatin及其相关物质及其用途

    公开(公告)号：US07795390B2

    公开(公告)日：2010-09-14

    申请号：US11474282

    申请日：2006-06-26

    申请人： Masatomo Mori ,  Hiroyuki Shimizu ,  Hiroshi Eguchi ,  Masanori Yamamoto

    发明人： Masatomo Mori ,  Hiroyuki Shimizu ,  Hiroshi Eguchi ,  Masanori Yamamoto

    IPC分类号： C12N9/00 ,  C12N1/20 ,  C12N15/00 ,  C07K14/00 ,  C07H21/02

    CPC分类号： C12Q1/6883 ,  A01K67/027 ,  A01K2227/105 ,  A01K2267/035 ,  C07K14/4702 ,  C12Q2600/158 ,  G01N33/5023 ,  G01N2800/02 ,  G01N2800/044

    摘要： The present invention relates to a novel method of obtaining a factor involved in appetite control and/or body weight control, as well as genes obtained by said method, polypeptides encoded by said genes, or novel polypeptides obtained from the information on polypeptides encoded by said genes as a means for treating, controlling or diagnosing diseases associated with eating disorders and/or body weight control. Also the present invention relates to substances that inhibit the effects of said genes or said polypeptides as a means for treating, controlling or diagnosing diseases associated with appetite control and/or body weight control. By using thiazolidine diones having a PPAR γ agonist activity, genes and polypeptides involved in appetite regulation and/or body weight reduction can be obtained. NESFATIN or the like obtained by said method can be used as a means for treating, controlling or diagnosing diseases associated with eating disorders and/or body weight control.

    摘要翻译： 本发明涉及一种获得涉及食欲控制和/或体重控制的因子的新方法，以及通过所述方法获得的基因，由所述基因编码的多肽或从由所述基因编码的多肽编码的信息获得的新多肽 基因作为治疗，控制或诊断与进食障碍和/或体重控制相关的疾病的手段。 本发明还涉及抑制所述基因或所述多肽作为治疗，控制或诊断与食欲控制和/或体重控制相关的疾病的手段的物质。 通过使用具有PPARγ激动剂活性的噻唑烷二酮，可以获得参与食欲调节和/或体重减轻的基因和多肽。 通过所述方法获得的NESFATIN等可以用作治疗，控制或诊断与进食障碍和/或体重控制相关的疾病的手段。

    COMPOSITION AND METHODS FOR OSTEOGENIC GENE THERAPY
    26.
    发明申请
    COMPOSITION AND METHODS FOR OSTEOGENIC GENE THERAPY 有权
    组合物和方法用于卵泡基因治疗

    公开(公告)号：US20100221232A1

    公开(公告)日：2010-09-02

    申请号：US11452873

    申请日：2006-06-13

    申请人： Kin-Hing William Lau ,  David J. Baylink ,  Susan L. Hall ,  Shin-Tai Chen ,  Subburaman Mohan

    发明人： Kin-Hing William Lau ,  David J. Baylink ,  Susan L. Hall ,  Shin-Tai Chen ,  Subburaman Mohan

    IPC分类号： A61K35/28 ,  A61P19/08 ,  A61P19/10 ,  A61K35/14

    CPC分类号： C07K14/50 ,  A01K2207/12 ,  A01K2267/035 ,  A61K38/1825 ,  C12N15/11 ,  C12N2799/027

    摘要： The present disclosure provides compositions and methods for increasing bone growth and/or enhancing wound healing, for example, fracture repair. The disclosure provides recombinant nucleic acids useful for promoting bone growth. For example, the disclosure provides recombinant nucleic acids that encode a fibroblast growth factor-2 (FGF-2) analog. The disclosure also provides vectors and cells incorporating these nucleic acids, as well as FGF-2 analogs encode by them. The disclosure also provides a mouse system of bone marrow transplantation and methods for producing as well as methods for using the system. Methods for inducing division and/or inducing differentiation of a hematopoietic stem cell are also provided, as are methods for enhancing bone growth and/or wound repair (for example, fracture repair).

    摘要翻译： 本公开提供了用于增加骨生长和/或增强伤口愈合的组合物和方法，例如骨折修复。 本公开提供了可用于促进骨生长的重组核酸。 例如，本公开提供编码成纤维细胞生长因子-2（FGF-2）类似物的重组核酸。 本公开还提供了掺入这些核酸的载体和细胞，以及由它们编码的FGF-2类似物。 本公开还提供了骨髓移植的小鼠系统以及用于生产的方法以及使用该系统的方法。 还提供诱导造血干细胞分化和/或诱导分化的方法，以及用于增强骨生长和/或伤口修复（例如，骨折修复）的方法。

    Protein formulations comprising s1-5
    29.
    发明申请
    Protein formulations comprising s1-5 审中-公开
    包含s1-5的蛋白质​​制剂

    公开(公告)号：US20090276863A1

    公开(公告)日：2009-11-05

    申请号：US11631040

    申请日：2005-07-01

    申请人： Toshihiro Nakajima ,  Naoko Yagishita ,  Tetsuya Amano

    发明人： Toshihiro Nakajima ,  Naoko Yagishita ,  Tetsuya Amano

    IPC分类号： A61K49/00 ,  A01K67/027 ,  C12N5/10 ,  C12N15/09 ,  G01N33/567 ,  G01N33/00 ,  C07K14/00 ,  A61K38/16 ,  C07K16/00 ,  A61P35/00

    CPC分类号： C07K14/475 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/035 ,  A61K38/00 ,  G01N33/5044

    摘要： The present inventors discovered that knockout mice whose S1-5 gene function is lost develop age-related diseases or symptoms. Histological analysis in such knockout mice revealed that bone mineral content, bone mineral density, and bone strength were decreased, and the number of osteoclasts in bone tissues was increased. Analysis of osteoclast-forming ability using bone marrow cells derived from the knockout mice revealed that osteoclast-forming ability is enhanced and osteoclasts are larger in the knockout mice than in wildtype mice. When purified S1-5 protein was added to this in vitro system, osteoclast-forming ability was inhibited.

    摘要翻译： 本发明人发现S1-5基因功能丧失的敲除小鼠发生与年龄相关的疾病或症状。 在这种敲除小鼠中的组织学分析显示，骨矿物质含量，骨矿物质密度和骨强度降低，骨组织中破骨细胞数量增加。 使用衍生自敲除小鼠的骨髓细胞破骨细胞形成能力的分析显示，在野生型小鼠中，敲除小鼠的破骨细胞形成能力增强，破骨细胞较大。 当纯化的S1-5蛋白加入体外时，破骨细胞形成能力受到抑制。